All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
This product is the plasmid containing an encoded anti-ENO2 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.
| Sub CAT. | DMAb Clone | DMAb Host | Target Species | DMAb Isotype | DMAb Immunogen | |
| DMAb-3419-FY | 5E2 | Mouse | Guinea Pig | IgG2a | ||
| DMAb-3421-FY | AT17D10 | Mouse | Human | IgG2b, κ | Recombinant human NSE purified from E.coli. Immunogen type: Recombinant protein. | |
| DMAb-3422-FY | BBS-NC-VI-H14 | Mouse | IgG1 | Purified Human gamma-gamma Enolase | ||
| DMAb-3423-FY | NSEP2 | Mouse | Human | IgG1, κ | Ovalbumin-conjugated synthetic peptides corresponding to human NSE amino acid sequence: TGDQLGALYQDFVRD | |
| DMAb-3463CQ | BA0108 | Rabbit | IgG | Human NSE aa 200-350 | ||
| DMAb-3464CQ | ENO2/1462 | Mouse | IgG2b | Human NSE aa 416-433 | ||
| DMAb-3465CQ | SPM347 | Mouse | Human | IgG2b | Human NSE aa 416-433 | |
| DMAb-3466CQ | ENO2/1375 | Mouse | IgG2b | Synthetic peptide within Human NSE aa 416-433 | ||
| DMAb-3467CQ | BA0013 | Rabbit | Human | IgG | Human REEP5 aa 150 to the C-terminus | |
| DMAb-3468CQ | BA0239 | Rabbit | IgG | Synthetic peptide from residues in human NSE | ||
| DMAb-3470CQ | 37E4 | Mouse | IgG1 | Recombinant full length protein | ||
| DMAb-3471CQ | 85F11 | Mouse | IgG2a, κ | Recombinant full length protein | ||
| DMAb-3472CQ | BA0240 | Rabbit | IgG | Synthetic peptide | ||
| DMAb-3473CQ | NSE-P1 | Mouse | Human | IgG1 | C terminal amino acids 416-433 of NSE |
There are currently no customer reviews or questions for Anti-ENO2 DNA-encoded mAb (DMAb), pVAX1 (DMAb-3419-FY). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION